<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Kurstriggere i Genmab i sep. 2019]]></title><description><![CDATA[<p dir="auto">9-12/9 IASLC 2019 WCLC: AXL ADC præsenteres oralt.</p>
<p dir="auto">12-15/9 17th International Myeloma Workshop: 13 abstracts fra Janssen/Genmab bl.a. 4 orale præsentationer (Griffin og PLEIADES) - plus andet godt !</p>
<p dir="auto">13/9 ECTRIMS: Ofatumumab fase III data i MS præsenteres (abstracts formentlig den 11/9). Ocrevus vil nå omsætning på 3,75 milliarder dollars i år.</p>
<p dir="auto">26/9 PDUFA dato for DVTd i MM (CASSIOPEIA)</p>
<p dir="auto">Med tak til Sukkeralf.</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/440220/kurstriggere-i-genmab-i-sep-2019</link><generator>RSS for Node</generator><lastBuildDate>Wed, 15 Jul 2026 11:06:20 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/440220.rss" rel="self" type="application/rss+xml"/><pubDate>Tue, 03 Sep 2019 07:24:29 GMT</pubDate><ttl>60</ttl></channel></rss>